SOPHiA GENETICS (NASDAQ:SOPH) CEO Ross Muken Sells 9,838 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Ross Muken sold 9,838 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $79,982.94. Following the sale, the chief executive officer directly owned 660,391 shares of the company’s stock, valued at $5,368,978.83. This represents a 1.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, September 21st, Ross Muken sold 422 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.33, for a total value of $3,515.26.

SOPHiA GENETICS Stock Down 3.1%

NASDAQ:SOPH traded down $0.23 during trading hours on Wednesday, reaching $7.15. 432,750 shares of the stock were exchanged, compared to its average volume of 308,157. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. SOPHiA GENETICS SA has a twelve month low of $3.75 and a twelve month high of $8.98. The firm has a 50 day moving average of $7.82 and a 200 day moving average of $6.12. The stock has a market cap of $599.81 million, a PE ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

SOPH has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. HC Wainwright lifted their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. AWM Investment Company Inc. acquired a new position in shares of SOPHiA GENETICS during the second quarter valued at about $9,809,000. Principal Financial Group Inc. raised its holdings in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares during the last quarter. Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the 1st quarter worth about $2,157,000. Sei Investments Co. bought a new position in SOPHiA GENETICS in the 1st quarter valued at about $1,772,000. Finally, 1492 Capital Management LLC lifted its position in SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after acquiring an additional 17,406 shares in the last quarter. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.